The effect of routine vaccination on invasive pneumococcal infections in Canadian children, Immunization Monitoring Program, Active 2000-2007

Vaccine

Volumn 28, Issue 9, 2010, Pages 2130-2136

  Bettinger, Julie A ^a   Scheifele, David W ^a   Kellner, James D ^b   Halperin, Scott A ^c   Vaudry, Wendy ^d   Law, Barbara ^e   Tyrrell, Gregory ^f  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c DALHOUSIE UNIVERSITY   (Canada)

^d UNIVERSITY OF ALBERTA   (Canada)

^e PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^f National Centre for Streptococcus   (Canada)

Author keywords

Conjugate pneumococcal vaccine

Indexed keywords

CEFOTAXIME; CEFTRIAXONE; PENICILLIN G; PNEUMOCOCCUS VACCINE;

ADOLESCENT; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; CANADA; CHILD; FEMALE; HEALTH SURVEY; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; NEWBORN; PENICILLIN RESISTANCE; PNEUMOCOCCAL INFECTION; PRESCHOOL CHILD; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; SCHOOL CHILD; SEROTYPE; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

ADOLESCENT; CANADA; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; IMMUNIZATION PROGRAMS; INFANT; MALE; MICROBIAL SENSITIVITY TESTS; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; POPULATION SURVEILLANCE; SEROEPIDEMIOLOGIC STUDIES; STREPTOCOCCUS PNEUMONIAE;

EID: 76949094005     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.12.026     Document Type: Article

References (48)

1. Schuchat A., Robinson K., Wenger J.D., Harrison L.H., Farley M., Reingold A.L., et al. Bacterial meningitis in the United States in 1995. Active Surveillance Team. N Engl J Med 337 October (14) (1997) 970-976
2. In: Marchessault V. (Ed). Canadian immunization guide. 6th ed. (2002), Canadian Medical Association, Ottawa
3. Robinson K.A., Baughman W., Rothrock G., Barrett N.L., Pass M., Lexau C., et al. Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: opportunities for prevention in the conjugate vaccine era. JAMA 285 April (13) (2001) 1729-1735
4. Scott J.A., Hall A.J., Dagan R., Dixon J.M., Eykyn S.J., Fenoll A., et al. Serogroup-specific epidemiology of Streptococcus pneumoniae: associations with age, sex, and geography in 7,000 episodes of invasive disease. Clin Infect Dis 22 June (6) (1996) 973-981
5. Hausdorff W.P., Yothers G., Dagan R., Kilpi T., Pelton S.I., Cohen R., et al. Multinational study of pneumococcal serotypes causing acute otitis media in children. Pediatr Infect Dis J 21 November (11) (2002) 1008-1016
6. Sniadack D.H., Schwartz B., Lipman H., Bogaerts J., Butler J.C., Dagan R., et al. Potential interventions for the prevention of childhood pneumonia: geographic and temporal differences in serotype and serogroup distribution of sterile site pneumococcal isolates from children-implications for vaccine strategies. Pediatr Infect Dis J 14 June (6) (1995) 503-510
7. Robbins J.B., Austrian R., Lee C.J., Rastogi S.C., Schiffman G., Henrichsen J., et al. Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups. J Infect Dis 148 December (6) (1983) 1136-1159
8. Hausdorff W.P., Bryant J., Paradiso P.R., and Siber G.R. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin Infect Dis 30 January (1) (2000) 100-121
9. Hausdorff W.P., Bryant J., Kloek C., Paradiso P.R., and Siber G.R. The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use. Part II. Clin Infect Dis 30 January (1) (2000) 122-140
10. An Advisory Committee Statement (ACS), and National Advisory Committee on Immunization (NACI). Statement on recommended use of pneumococcal conjugate vaccine. Can Commun Dis Rep 28 January (Pt 2) (2002) 1-32
11. Immunization coverage by age 2 for five recommended vaccines in the Capital Health region (Edmonton). Can Commun Dis Rep 32 May (10) (2006) 117-121
12. Two-year olds with up-to-date immunizations (2009). http://www.bccdc.ca/default.htm [PDF report] January 30 [cited February 15, 2009]. Available from:
13. Manitoba immunization monitoring system annual report. Manitoba immunization report (2006). http://www.gov.mb.ca/health/publichealth/cdc/surveillance/mims06.pdf [PDF report] [cited February 15, 2009]. Available from:
14. Scheifele D.W. IMPACT after 17 years: lessons learned about successful networking. Paediatr Child Health 14 January (1) (2009) 33-35
15. In: Naus M. (Ed). Canadian immunization guide. 7th ed. (2006), Public Health Agency of Canada, Ottawa
16. Lovgren M., Spika J.S., and Talbot J.A. Invasive Streptococcus pneumoniae infections: serotype distribution and antimicrobial resistance in Canada, 1992-1995. CMAJ 158 February (3) (1998) 327-331
17. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. 7th ed. (2006), CLSI, Wayne, PA, USA
18. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; 17th informational supplement M100-S17 (2007), CLSI, Wayne, PA, USA
19. Scheifele D.W., Halperin S.A., Pelletier L., Talbot J., Lovgren M., Vaudry W., et al. Reduced susceptibility to penicillin among pneumococci causing invasive infection in children, Canada, 1991-1998. Can J Infect Dis 12 July/August (4) (2001) 241-246
20. Bettinger J.A., Scheifele D.W., Halperin S.A., Kellner J.D., and Tyrrell G. Invasive pneumococcal infections in Canadian children, 1998-2003: implications for new vaccination programs. Can J Public Health 98 March-April (2) (2007) 111-115
21. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; 18th informational supplement M100-S18 (2008), CLSI, Wayne, PA, USA
22. Bjornson G., Scheifele D.W., Bettinger J.A., Patrick D., Gustafson L., Daly P., et al. Effectiveness of pneumococcal conjugate vaccine in greater Vancouver, Canada: 2004-2005. Pediatr Infect Dis J 26 June (6) (2007)
23. Paulus S., David S., Tang W., Winters M., Buxton J., Henry B., et al. Incidence of invasive pneumococcal disease after introduction of the Universal Infant Immunization Program, British Columbia (2002-2005). Can Commun Dis Rep 32 July (14) (2006) 157-161
24. Kellner J.D., Church D.L., MacDonald J., Tyrrell G.J., and Scheifele D. Progress in the prevention of pneumococcal infection. CMAJ 173 November (10) (2005) 1149-1151
25. Laupland K.B., Gregson D.B., Vanderkooi O.G., Ross T., and Kellner J.D. The changing burden of pediatric bloodstream infections in Calgary, Canada, 2000-2006. Pediatr Infect Dis J 28 February (2) (2009) 114-117
26. De Wals P., Robin E., Fortin E., Thibeault R., Ouakki M., and Douville-Fradet M. Pneumonia after implementation of the pneumococcal conjugate vaccine program in the province of Quebec, Canada. Pediatr Infect Dis J 27 November (11) (2008) 963-968
27. Kellner J.D., Vanderkooi O.G., Macdonald J., Church D.L., Tyrrell G.J., and Scheifele D.W. Changing epidemiology of invasive pneumococcal disease in Canada, 1998-2007: update from the Calgary-Area Streptococcus pneumoniae Research (CASPER) Study. Clin Infect Dis 49 July (2) (2009) 205-212
28. Tyrrell G.J., Lovgren M., Chui N., Minion J., Garg S., Kellner J.D., et al. Serotypes and antimicrobial susceptibilities of invasive Streptococcus pneumoniae pre and post 7 valent pneumococcal conjugate vaccine introduction in Alberta, Canada, 2000-2006. Vaccine 27 June (27) (2009) 3553-3560
29. Whitney C.G., Farley M.M., Hadler J., Harrison L.H., Bennett N.M., Lynfield R., et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 348 May (18) (2003) 1737-1746
30. Talbot T.R., Poehling K.A., Hartert T.V., Arbogast P.G., Halasa N.B., Mitchel E., et al. Reduction in high rates of antibiotic-nonsusceptible invasive pneumococcal disease in Tennessee after introduction of the pneumococcal conjugate vaccine. Clin Infect Dis 39 September (5) (2004) 641-648
31. Poehling K.A., Talbot T.R., Griffin M.R., Craig A.S., Whitney C.G., Zell E., et al. Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine. JAMA 295 April (14) (2006) 1668-1674
32. Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction-eight states, 1998-2005. MMWR Morb Mortal Wkly Rep 57 Feb (6) (2008) 144-148
33. Hicks L.A., Harrison L.H., Flannery B., Hadler J.L., Schaffner W., Craig A.S., et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J Infect Dis 196 November (9) (2007) 1346-1354
34. Messina A.F., Katz-Gaynor K., Barton T., Ahmad N., Ghaffar F., Rasko D., et al. Impact of the pneumococcal conjugate vaccine on serotype distribution and antimicrobial resistance of invasive Streptococcus pneumoniae isolates in Dallas, TX, children from 1999 through 2005. Pediatr Infect Dis J 26 June (6) (2007) 461-467
35. Huang S.S., Platt R., Rifas-Shiman S.L., Pelton S.I., Goldmann D., and Finkelstein J.A. Post-PCV7 changes in colonizing pneumococcal serotypes in 16 Massachusetts communities, 2001 and 2004. Pediatrics 116 September (3) (2005) e408-e413
36. Dagan R. Serotype replacement in perspective. Vaccine 27 August (Suppl. 3) (2009) C22-C24
37. Pai R., Moore M.R., Pilishvili T., Gertz R.E., Whitney C.G., and Beall B. Postvaccine genetic structure of Streptococcus pneumoniae serotype 19A from children in the United States. J Infect Dis 192 December (11) (2005) 1988-1995
38. Pelton S.I. Replacement pneumococcal disease in perspective. Clin Infect Dis 46 May (9) (2008) 1353-1355
39. Pichichero M.E., and Casey J.R. Emergence of a multiresistant serotype 19A pneumococcal strain not included in the 7-valent conjugate vaccine as an otopathogen in children. JAMA 298 October (15) (2007) 1772-1778
40. Dawar M., Russell B., McClean K., Levett P.N., Tyrell G.J., and Irvine J. A case of necrotizing fasciitis due to Streptococcus pneumoniae serotype 5 in Saskatchewan. Can J Infect Dis 19 January/February (1) (2008) 69-71
41. Romney M.G., Hull M.W., Gustafson R., Sandhu J., Champagne S., Wong T., et al. Large community outbreak of Streptococcus pneumoniae serotype 5 invasive infection in an impoverished, urban population. Clin Infect Dis 47 September (6) (2008) 768-774
42. Feikin D.R., and Klugman K.P. Historical changes in pneumococcal serogroup distribution: implications for the era of pneumococcal conjugate vaccines. Clin Infect Dis 35 September (5) (2002) 547-555
43. Richter S.S., Heilmann K.P., Dohrn C.L., Riahi F., Beekmann S.E., and Doern G.V. Changing epidemiology of antimicrobial-resistant Streptococcus pneumoniae in the United States, 2004-2005. Clin Infect Dis 48 February (3) (2009) e23-e33
44. Farrell D.J., Klugman K.P., and Pichichero M. Increased antimicrobial resistance among nonvaccine serotypes of Streptococcus pneumoniae in the pediatric population after the introduction of 7-valent pneumococcal vaccine in the United States. Pediatr Infect Dis J 26 February (2) (2007) 123-128
45. Dagan R., and Klugman K.P. Impact of conjugate pneumococcal vaccines on antibiotic resistance. Lancet Infect Dis 8 December (12) (2008) 785-795
46. Emergence of antimicrobial-resistant serotype 19A Streptococcus pneumoniae-Massachusetts, 2001-2006. MMWR Morb Mortal Wkly Rep 56 October (41) (2007) 1077-1080
47. Effects of new penicillin susceptibility breakpoints for Streptococcus pneumoniae-United States, 2006-2007. MMWR Morb Mortal Wkly Rep 57 December (50) (2008) 1353-1355
48. Statistics Canada (2009). [accessed November 2009, 12]. Available from: http://www12.statcan.ca/english/census06/data/highlights/agesex/pages/Page.cfm?Lang=E&Geo=PR&Code=01&Table=1&Data=Change&Sex=1&StartRec=1&Sort=2&Display=Page